Cortechs.ai | Dr. Ana M. Franceschi Joins Cortechs.ai Medical Advisory Board

Dr. Ana M. Franceschi Joins Cortechs.ai Medical Advisory Board

Neuroimaging thought leader to enhance PET/MRI and dementia research impact through AI-powered tools

San Diego, CA – Cortechs.ai is proud to announce the appointment of Dr. Ana M. Franceschi, MD, PhD, to its Medical Advisory Board. A nationally recognized expert in molecular neuroimaging and hybrid brain imaging techniques, Dr. Franceschi brings an outstanding track record of translational research and clinical leadership in dementia-focused imaging. She currently serves as Associate Professor of Radiology, Director of Dementia Imaging, and Director of Molecular Neuroimaging at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Lenox Hill Hospital in New York, NY.

With over 20 years of clinical and research experience, Dr. Franceschi has dedicated her career to advancing neuroimaging approaches in Alzheimer’s disease and related neurocognitive disorders. She has been a user and advocate of NeuroQuant since 2017, further underscoring her commitment to integrating advanced imaging technologies into routine clinical practice.

“We are honored to welcome Dr. Franceschi to the Cortechs.ai Medical Advisory Board,” said Kyle Frye, Chief Executive Officer of Cortechs.ai. “We admire her shared passion for enhancing patient care through innovation and her insights will be invaluable as we expand our AI-powered solutions to address the complexities of neurodegenerative disease.”

By joining Cortechs.ai’s advisory board, Dr. Franceschi will help shape the future of AI-enhanced neuroimaging tools, contributing her expertise to ensure clinical relevance and alignment with emerging diagnostic standards.

Dr. Franceschi stated, “I’m excited to join Cortechs.ai’s Medical Advisory Board at such a pivotal moment in the evolution of neuroimaging. Integrating AI into routine clinical practice is no longer a future aspiration—it’s a present necessity. I look forward to contributing my clinical perspective to help drive impactful, real-world applications.”

With this appointment, Cortechs.ai continues to strengthen its commitment to integrating top-tier clinical expertise into its development process, ensuring that its tools support physicians and researchers in providing the best possible care for patients.

For more information about Cortechs.ai and its cutting-edge imaging solutions, visit www.cortechs.ai.

About Cortechs.ai

Cortechs.ai is a leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and early detection, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical device software that provides quantitative MR imaging analysis to assist clinicians in assessing neurodegeneration, as well as brain and prostate cancer. Cortechs.ai’s industry-leading imaging solutions offer radiologists, oncologists, and urologists a streamlined, cost-effective way to assess brain and prostate health, including cancer evaluation. The company also offers FDA-cleared products for evaluating neurological disorders such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, tumors, and other brain abnormalities. For more information, please visit www.cortechs.ai and follow us on Twitter, LinkedIn, and Facebook.

 

For more information, please contact:

___________

info@cortechs.ai

+1 858 459 9700

More Resources

05/29/2025

Enhancing Imaging Workflow with DICOM SR: NeuroQuant®’s Seamless Integration 

As imaging becomes more data-driven, tools like NeuroQuant® with DICOM SR support pave the way for smarter, more connected radiology

05/18/2025

Cortechs.ai and ALZ-NET Announce Strategic Collaboration to Improve Alzheimer’s Disease Care Through AI-Driven Imaging

This new strategic collaboration aims to enhance the quality of care for people living with Alzheimer’s disease.

05/16/2025

Case Study: NeuroQuant® for ARIA: Monitoring ARIA Progression in Early Alzheimer’s Disease

Dr. Suzie Bash highlights how advanced imaging with NeuroQuant for ARIA supported detection and monitoring of ARIA-E and ARIA-H in an 81-year-old patient.

05/13/2025

Dr. Ana M. Franceschi Joins Cortechs.ai Medical Advisory Board

Neuroimaging thought leader to enhance PET/MRI and dementia research impact through AI-powered tools

05/10/2025

All the Ways to Use the NeuroQuant Custom Report

With the ability to select structures from NeuroQuant’s 70+ structure parcellation atlas, the user has the power to truly personalize patient care!

05/04/2025

Introducing NeuroQuant MS Lesion Dynamics Computation: A Clearer Path to Understanding Disease Progression

Discover how the latest NeuroQuant MS update offers a clearer, more intuitive way to track lesion changes and understand disease progression over time.
Scroll to Top